Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring < b > < i > EGFR < /i > < /b > Exon 19 Deletion and Exon 21 L858R Substitution
Conclusion: Del19 and L858R have distinct prognostic implications and may require individual therapeutic strategies.Chemotherapy 2017;62:151-158 (Source: Chemotherapy)
Source: Chemotherapy - January 20, 2017 Category: Cancer & Oncology Source Type: research
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis
Leptomeningeal metastases occur in 1% of patients with non-small-cell lung cancer. There have been several reports on the treatment of leptomeningeal metastases with afatinib. Our patient was a 41-year-old woman who had never smoked and was diagnosed with stage IV adenocarcinoma of the lung with an epidermal growth factor receptor (EGFR) mutation. She was treated with afatinib for the recurrence of leptomeningeal metastases. After the treatment with afatinib was initiated, the neurological symptoms dramatically regressed, and she achieved progression-free survival for 7 months. The concentration of afatinib in the cerebros...
Source: Chemotherapy - December 28, 2016 Category: Cancer & Oncology Source Type: research
A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes
Conclusions: In this prospective study, the incidences of HSR were similar with generic and original paclitaxel but significantly different with generic and original docetaxel.Chemotherapy 2017;62:134-139 (Source: Chemotherapy)
Source: Chemotherapy - December 20, 2016 Category: Cancer & Oncology Source Type: research
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20%
We report a case of composite NHL in a patient who received frontline bendamustine with rituximab with encouraging results. Our patient had a left ventricular ejection fraction of 20%, making her a poor candidate for anthracycline-based therapy. We opted to administer bendamustine with rituximab for a total of 6 cycles. She remains disease free 18 months after the completion of therapy.Chemotherapy 2017;62:140-146 (Source: Chemotherapy)
Source: Chemotherapy - December 13, 2016 Category: Cancer & Oncology Source Type: research
Biofilm Formation Restrained by Subinhibitory Concentrations of Tigecyclin in Acinetobacter baumannii Is Associated with Downregulation of Efflux Pumps
Conclusion: Our results suggest that downregulation of efflux pumps, especially theAdeFGH efflux pump, is probably responsible for the decline in biofilm formation inA. baumannii treated with subinhibitory concentrations of tigecyclin.Chemotherapy 2017;62:128-133 (Source: Chemotherapy)
Source: Chemotherapy - November 7, 2016 Category: Cancer & Oncology Source Type: research
Biofilm Formation Restrained by Subinhibitory Concentrations of Tigecyclin in < b > < i > Acinetobacter baumannii < /i > < /b > Is Associated with Downregulation of Efflux Pumps
Conclusion: Our results suggest that downregulation of efflux pumps, especially theAdeFGH efflux pump, is probably responsible for the decline in biofilm formation inA. baumannii treated with subinhibitory concentrations of tigecyclin.Chemotherapy 2017;62:128-133 (Source: Chemotherapy)
Source: Chemotherapy - November 4, 2016 Category: Cancer & Oncology Source Type: research
Adaptive Cross-Resistance to Aminoglycoside Antibiotics in Pseudomonas aeruginosa Induced by Topical Dosage of Neomycin
Conclusions: Our findings suggest thatP. aeruginosa can survive in the presence of neomycin with a concentration typically used in topical dosage forms, and that the acquired adaptive resistance is persistent and is accompanied by cross-resistance to other aminoglycosides.Chemotherapy 2017;62:121-127 (Source: Chemotherapy)
Source: Chemotherapy - October 31, 2016 Category: Cancer & Oncology Source Type: research
Adaptive Cross-Resistance to Aminoglycoside Antibiotics in < b > < i > Pseudomonas aeruginosa < /i > < /b > Induced by Topical Dosage of Neomycin
Conclusions: Our findings suggest thatP. aeruginosa can survive in the presence of neomycin with a concentration typically used in topical dosage forms, and that the acquired adaptive resistance is persistent and is accompanied by cross-resistance to other aminoglycosides.Chemotherapy 2017;62:121-127 (Source: Chemotherapy)
Source: Chemotherapy - October 28, 2016 Category: Cancer & Oncology Source Type: research
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions
This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.Chemotherapy 2017;62:111-120 (Source: Chemotherapy)
Source: Chemotherapy - October 28, 2016 Category: Cancer & Oncology Source Type: research
In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant < b > < i > Pseudomonas aeruginosa < /i > < /b >
This study evaluated the antimicrobial activities of various combination therapies againstP. aeruginosa with high antimicrobial resistance, including multidrug-resistantP. aeruginosa (MDRP) using an in vitro and in vivo study.Methods: We evaluated 24 combination therapies, including colistin, aztreonam, meropenem, ceftazidime, ciprofloxacin, amikacin, rifampicin, arbekacin and piperacillin against 15 MDRP isolates detected at Aichi Medical University Hospital with the break-point checkerboard method. Based on the results of the in vitro study, we evaluated antimicrobial activity against highly antimicrobial-resistantP. aer...
Source: Chemotherapy - October 27, 2016 Category: Cancer & Oncology Source Type: research
Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes
Conclusions: This retrospective study adds to the limited literature exploring alternative therapies for complicated and MDR UTIs with results providing additional evidence that fosfomycin may be an effective oral option.Chemotherapy 2017;62:100-104 (Source: Chemotherapy)
Source: Chemotherapy - October 27, 2016 Category: Cancer & Oncology Source Type: research
Lysosome Inhibitors Enhance the Chemotherapeutic Activity of Doxorubicin in HepG2 Cells
The lysosome inhibitors bafilomycin A1 and chloroquine have both lysosomotropic properties and autophagy inhibition ability, and are promising clinical agents to be used in combination with anticancer drugs. In order to investigate this combination effect, HepG2 cells were treated with bafilomycin A1, chloroquine, or/and doxorubicin, and their proliferative ability, induction of apoptosis, and the changes of lysosomal membrane permeabilization and mitochondrial membrane potential were studied. The results demonstrate that treatment with bafilomycin A1 or chloroquine alone at a relatively low concentration promotes the inhi...
Source: Chemotherapy - October 20, 2016 Category: Cancer & Oncology Source Type: research
Acknowledgement to Reviewers
Chemotherapy 2015 –16;61:331–331 (Source: Chemotherapy)
Source: Chemotherapy - October 20, 2016 Category: Cancer & Oncology Source Type: research
Contents Vol. 61, 2015/2016
Chemotherapy 2015 –16;61:I–IV (Source: Chemotherapy)
Source: Chemotherapy - October 20, 2016 Category: Cancer & Oncology Source Type: research
Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against < b > < i > Propionibacterium acnes < /i > < /b >
Determination of the mutant prevention concentration (MPC) and the mutant selection window (MSW) of antimicrobial agents used to treat pathogenic bacteria is important in order to apply effective antimicrobial therapies. Here, we determined the MPCs of the major topical antimicrobial agents againstPropionibacterium acnes andStaphylococcus aureus which cause skin infections and compared their MSWs. Among the MPCs of nadifloxacin and clindamycin, the clindamycin MPC was determined to be the lowest againstP. acnes. In contrast, the nadifloxacin MPC was the lowest againstS. aureus. Calculations based on the minimum inhibitory ...
Source: Chemotherapy - October 20, 2016 Category: Cancer & Oncology Source Type: research
